Clinical trial · Observational
Long Acting GnRH Antagonist in PCOS Women Undergoing IVF
The Use of a Long Acting GnRH Antagonist (Degarelix) in Controlled Ovarian Hyperstimulation in PCOS Women at a Risk to Developing OHSS Undergoing IVF : a Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PCOS is a common endocrinopathy affecting 5-10% of women in their reproductive age characterized by hyperandrogenism, chronic anovulation and polycystic ovaries. This syndrome is a serious problem in IVF since there is a high risk of developing ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation with gonadotropins. The introduction of GnRH antagonist in IVF has reduced the incidence of severe OHSS, still maintaining a good ovarian response and pregnancy rate. Recently, a long acting GnRH antagonist, Degarelix, was introduced for prostatic cancer treatment. Furthermore a recent paper reported its use also for the induction of multiple follicular growth in a program of oocyte donation. The aim of this study is to evaluate the feasibility of GnRH antagonist depot use in a protocol of controlled ovarian hyperstimulation in PCOS women at risk of developing OHSS in IVF cycles.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Invitro Fertilization | — | UNRESOLVED | — |
| Ovarian Hyperstimulation Syndrome | — | UNRESOLVED | — |
| Polycystic Ovarian Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GnRH antagonist depot Degarelix | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- GnRH antagonist depot, Degarelix
- description
- Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
- interventionNames
- Drug: GnRH antagonist depot Degarelix
Primary outcomes (2)
- measure
- Pregnancy rate
- timeFrame
- Time Frame: until 12th gestational week
- measure
- Incidence of OHSS
- timeFrame
- Time frame: until 7th gestational week
Secondary outcomes (5)
- measure
- Number of collected oocytes
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 23 Years
- Maximum age
- 37 Years
Show eligibility criteria text
Inclusion Criteria: * regular menstrual cycle (26-39 days) * primary infertility * BMI \< 30 Exclusion Criteria: * women with diabetes and other metabolic disease * women with heart disease * women with inflammatory or autoimmune disease
References
Publications (0)
Data not yet available